We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current METXF market cap is 0. The company's latest EPS is CAD and P/E is N/A.
Year End 31 August 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Total Revenue | 0 | 0 |
Operating Income | -70k | -640k |
Net Income | -145k | -6.52M |
Year End 31 August 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Total Assets | 102k | 672k |
Total Liabilities | 233k | 149k |
Total Equity | -131k | 523k |
Year End 31 August 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Operating | -136k | -303k |
Investing | N/A | 757k |
Financing | 140k | 116k |
Market Cap | 0 |
Price to Earnings Ratio | N/A |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 0 |
Price to Book Ratio | 0 |
Dividend Yield | - |
Shares Outstanding | 23.56M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0 (0%) |
Company Name | Me Therapeutics Holdings Inc (PK) |
Address |
177 robson street vancouver, british columbia V6C 0A3. |
Website | https://www.metherapeutics.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions